Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LXEO
LEXEO THERAPEUTICS, INC. COMMON STOCK
NASDAQ
$4.84
▲ UP 1.26% (0.06)

KEY STATISTICS

Market Cap$372.59 M
52w High$10.99
52w Low$3.99
Dividend Yield—
Frequency—
P/E-3.34
Volume311.34K
Shares Out.78.52M

COMPANY

LEADERSHIP

R. Nolan Townsend
CHIEF EXECUTIVE
R. Nolan Townsend

COMPENSATION 2026

Salary$632,700
Stock Awards$1,493,488
Incentive Plan Pay$347,985
All Other Comp.$10,785
Total$3,650,940

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 3, 2023
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
63

PRICE TARGET

Target High$30.00
Target Low$10.00
Target Median$20.00
Target Consensus$21.13

UPCOMING EARNINGS

DateDec 14, 2026
DayMonday
Rev. Est.—
DEC
14
MON

PRICE

$4.84 ▲ UP 1.26% (+$0.06)
$4.72$4.80$4.889:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.84

About Lexeo Therapeutics, Inc. Common Stock

https://www.lexeotx.com ↗

Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company founded in 2017 in New York, develops AAVrh10-based gene therapies for hereditary and acquired diseases, including Friedreich's ataxia, cardiomyopathies, APOE4-related conditions,...

INDUSTRY

Biotechnology

A PRODUCT LEXEO THERAPEUTICS, INC. COMMON STOCK IS KNOWN FOR

LX2006
LX2006

LX2006 is an investigational gene therapy for Friedreich's ataxia cardiomyopathy, receiving multiple FDA designations, currently in Phase 1/2 trials, with plans for a registrational study.

COMPETITORS

COMPETITOR
RCKT COMPARE
SLDB COMPARE
SRPT COMPARE
TNYA COMPARE
VYGR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
83
LISTED HERE
14
RANKED BY POSITION SIZE
XBI
0.11% · 2.5M
VTS.AX
0.00% · 2.3M
XSU.TO
0.01% · 1.8M
FESM
0.02% · 283.8K
DFAS
0.01% · 254.1K
LABU
0.07% · 86.4K
BBC
0.68% · 71.8K
XRS2.F
0.01% · 64.8K
PRFZ
0.01% · 36.7K
RSSL
0.01% · 33.7K
AVSC
0.00% · 25.7K
URTY
0.00% · 2.9K
VETS
0.03% · 1.5K
RESM
0.01% · 120

INSTITUTIONAL OWNERSHIP

SHARES OWNED
70.25%
HOLDERS
170
TOP 12 OF 170 · RANKED BY POSITION SIZE
Paradigm Biocapital Advisors LP
6.2M sh · $35.5M
Janus Henderson Group Plc
6.1M sh · $40.49M
Blackrock, Inc.
5.1M sh · $29.34M
Affinity Asset Advisors, LLC
5.1M sh · $28.99M
Ra Capital Management, L.P.
5.0M sh · $49.65M
Vestal Point Capital, LP
4.5M sh · $44.44M
Frazier Life Sciences Management, L.P.
4.4M sh · $25.4M
Balyasny Asset Management L.P.
3.9M sh · $25.99M
Vanguard Group Inc
3.9M sh · $38.67M
Citadel Advisors LLC
3.8M sh · $22.01M
Orbimed Advisors LLC
3.6M sh · $20.68M
State Street Corp
3.6M sh · $20.48M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Townsend Richard Nolan
Sale · 3.3K shares
2026-08-18
★
OFFICER: CHIEF OPERATING OFFICER
Otero Jose Manuel
Sale · 1.3K shares
2026-08-18
★
OFFICER: CHIEF FINANCIAL OFFICER
Tamayo Louis Edward
Sale · 4.1K shares
2026-08-18
★
OFFICER: CHIEF MEDICAL OFFICER
Bhalla Narinder Pal
Purchase · 55.0K shares
2026-06-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 1
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Chardan Capital BUY HC Wainwright & Co. BUY Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
SLN$14.67COMPARE
CTNM$17.38COMPARE
CAPR$9.35COMPARE
KYTX$8.37COMPARE
LRMR$3.81COMPARE
DBVT$13.62COMPARE
VNDA$5.33COMPARE
AMRN$13.72COMPARE